Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07444684
PHASE2

A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

View on ClinicalTrials.gov

Summary

This study aims to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 Injection in patients with pyoderma gangrenosum.

Official title: A Phase II Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 Injection in Adult Patients With Pyoderma Gangrenosum

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2026-03-05

Completion Date

2028-04

Last Updated

2026-03-03

Healthy Volunteers

No

Interventions

DRUG

SHR-1139 Injection

SHR-1139 injection.

Locations (1)

Shandong First Medical University Affiliated Dermatology Hospital

Jinan, Shandong, China